The purpose of this study is to find out what effects, good and/or bad, the addition of lenalidomide to standard chemotherapy (RCHOP) has on you and your cancer. Everybody in this study will receive standard chemotherapy. In addition to standard chemotherapy randomly chosen half of the subjects will receive a medication called lenalidomide. Adding lenalidomide to the standard chemotherapy RCHOP is considered experimental in diffuse large B cell lymphoma, and is not FDA approved. There is NO placebo (“sugar pill”) in this study, and everybody selected will receive an active medication.
- Adequate organ function
- Newly diagnosed with stage III or IV classical Hodgkin Lymphoma and have not received treatments
- Any sensory or motor peripheral neuropathy
- Known human immunodeficiency virus (HIV) positive
Participants will receive the following study regimen with or without lenalidomide depending on randomization: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone. Participants will have physical exams, blood draws, PET/CT scans, and other procedures as per protocol. There will be about 10 visits during outpatient investigation drug regime and 2-3 year follow up and the end of study.